National Health (Price and Special Patient Contribution) Amendment Determination 2018 (No. 3) (PB 30 of 2018) (Cth)

PB 30 of 2018

National Health (Price and Special Patient Contribution) Amendment Determination 2018 (No. 3)

National Health Act 1953

___________________________________________________________________________

I, LISA LA RANCE, Assistant Secretary, Pricing and PBS Policy Branch, Technology Assessment and Access Division, Department of Health, delegate of the Minister for Health, make this Determination under section 85B of the National Health Act 1953.

Date 27^th April 2018

LISA LA RANCE

Assistant Secretary

Pricing and PBS Policy Branch

Technology Assessment and Access Division

Department of Health

_________________________________________________________________________

1. Name of Instrument

(1)This Instrument is the National Health (Price and Special Patient Contribution) Amendment Determination 2018 (No. 3).

(2)This Instrument may also be cited as PB 30 of 2018.

1. Commencement

This Instrument commences on 1 May 2018.

1. Amendment of the National Health (Price and Special Patient Contribution) Determination 2010 (PB 109 of 2010)

Schedule 1 amends the National Health (Price and Special Patient Contribution) Determination 2010 (PB 109 of 2010).

Schedule 1     Amendments

[1]Schedule 1, entry for Amlodipine with atorvastatin

omit:

Tablet 5 mg amlodipine (as besylate) with 10 mg atorvastatin (as calcium)	Oral	Caduet 5/10	30	2.25	5.04
Tablet 5 mg amlodipine (as besylate) with 20 mg atorvastatin (as calcium)	Oral	Caduet 5/20	30	2.93	5.72

[2]Schedule 1, entry for Olmesartan in the form Tablet containing olmesartan medoxomil 20 mg

(a)omit from the column headed “Determined Price”:           7.43        substitute:             5.63

(b)omit from the column headed “Claimed Price”:                 10.69     substitute:             8.10

[3]Schedule 1, entry for Olmesartan in the form Tablet containing olmesartan medoxomil 40 mg

(a)omit from the column headed “Determined Price”:           15.76     substitute:             11.94

(b)omit from the column headed “Claimed Price”:                 19.02     substitute:             14.41

[4]Schedule 1, entry for Telmisartan in the form Tablet 40 mg

(a)omit from the column headed “Determined Price”:           1.94        substitute:             1.65

(b)omit from the column headed “Claimed Price”:                 4.44substitute:             3.78

[5]Schedule 1, entry for Telmisartan in the form Tablet 80 mg

(a)omit from the column headed “Determined Price”:           5.61        substitute:             4.78

(b)omit from the column headed “Claimed Price”:                 8.11substitute:             6.91

[6]Schedule 1, entry for Telmisartan with amlodipine in the form Tablet 40 mg-5 mg (as besylate)

(a)omit from the column headed “Determined Price”:           2.71        substitute:             2.42

(b)omit from the column headed “Claimed Price”:                 5.21substitute:             4.65

[7]Schedule 1, entry for Telmisartan with amlodipine in the form Tablet 40 mg-10 mg (as besylate)

(a)omit from the column headed “Determined Price”:           3.31        substitute:             3.02

(b)omit from the column headed “Claimed Price”:                 5.81substitute:             5.30

[8]Schedule 1, entry for Telmisartan with amlodipine in the form Tablet 80 mg-5 mg (as besylate)

(a)omit from the column headed “Determined Price”:           6.38        substitute:             5.55

(b)omit from the column headed “Claimed Price”:                 8.88substitute:             7.72

[9]Schedule 1, entry for Telmisartan with amlodipine in the form Tablet 80 mg-10 mg (as besylate)

(a)omit from the column headed “Determined Price”:           6.98        substitute:             6.15

(b)omit from the column headed “Claimed Price”:                 9.48        substitute:             8.35